Rushin Patel MD
@rushin311
Cardiology Fellow @LaheyCardiology @LaheyHospital | Lahey IM alum | Wildlife Photography Enthusiast
ID: 2838250934
https://instagram.com/rushinwildlife?utm_source=ig_profile_share&igshid=14x3zg64r9kgu 02-10-2014 17:40:09
119 Tweet
436 Followers
611 Following
Team of researchers led by Lahey Hospital in collaboration with Brigham and Women's Hospital BIDMC UCSF Health et al 🤝 to study the impact of #Paxlovid use for #COVID19 on the development of #LongCovid Rushin Patel MD Saurabh S Dani, MD, MSc Dan McQuillen Sumanth Khadke MD Sarju Ganatra, MD, FACC et al.
What a fantastic time hosting the wonderful fellows, attending and leadership Lahey Medicine Lahey Hospital Lahey Cardiology for the summer cookout! We look forward to a fabulous year ahead and many more occasions to celebrate!
Incredibly proud of our fellow Rushin Patel MD for leading the crucial study of SGLT-2i and GLP1RA incremental benefits in HFpEF! Kudos to the dedicated mentors and fantastic team Sarju Ganatra, MD, FACC Saurabh S Dani, MD, MSc Javed Butler Gregg Fonarow MD Dr. Deepak L. Bhatt
#cardiology #cardioX JACC Journals
Thank you for the repost! Cardiology Today
Multi-Institute study in JACC Journals led by Lahey Hospital investigators shows incremental benefits of #GLP1RA in addition to #SGLT2i for those with #heartfailure #HFpEF #obesity #diabetes sciencedirect.com/science/articl…
Superb work by Lahey Cardiology stellar fellow Rushin Patel MD and fantastic collaborators led by Sarju Ganatra, MD, FACC !
#GCOS2024 #JACCCardioOnc SimPub: #SGLT2i administration was associated with a significantly decreased risk of developing cancer therapy-related cardiac dysfunction in patients with #T2DM and cancer. bit.ly/4ebDU7t #GCOS24 #CardioOnc #Diabetes #T2D Ammar Bhatti DO
SGLT2 inhibition may prevent cancer therapy-related cardiac dysfunction and improve other outcomes in patients with diabetes undergoing cancer therapy #GCOS2024 @HemoncToday #CardioOncology American College of Cardiology Read more👇 healio.com/news/cardiolog…
My comments re. future directions of #GLP1RA & #HeartFailureOutcomes | Efficacy of Semaglutide in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction | comment: Rushin Patel MD prac.co/l/2a7wbaht @practiceupdate #DouglasZipes Joerg Herrmann #BenScirica
New JACC Journals #JACCHF In patients with #T2DM, ⬆️ #BMI & #HFpEF ➡️ #GLP1 agonists provide incremental benefit in addition to #SGLT2i with ⬇️ in: ▪️HF exacerbation ▪️All cause hospitalization ▪️Atrial arrhythmias ▪️Pulmonary HTN ▪️AKI DOI: 10.1016/j.jchf.2024.07.006
New #JACCHF 📄: bit.ly/40xnSB9 In patients w/ #Obesity, #T2DM & #HFpEF➡️#GLP1 agonists provide incremental benefits in addition to #SGLT2i w/ reduction in: 🔸HF exacerbation 🔸All-cause 🏥 🔸Atrial arrhythmias 🔸AKI 🔸Pulmonary #HTN Rushin Patel MD Sarju Ganatra, MD, FACC
Patients w/ Heart Failure w/ Preserved Ejection Fraction rarely get palliative care yet our new 📜in JACC Journals led by the incomparable Sarju Ganatra, MD, FACC and Saurabh S Dani, MD, MSc shows immense benefits. When will we do right by our patients w/ heart failure? authors.elsevier.com/sd/article/S27…
In this #JACCCardioOnc study, Dr. Ammar Bhatti DO, et al highlight that #SGLT2 inhibitors 📉 the risk of CTRCD in pts w/ #T2DM & cancer, as well as lower #heartfailure exacerbations, mortality, & 🏥 jacc.org/doi/10.1016/j.… #CardioOncology #SGLT2i Anita Deswal Ana Barac, MD, PhD, FACC, FAHA
“Excited to share our latest editorial published in Circulation - Our study highlights T1 mapping as a novel marker for heart failure progression in hypertrophic cardiomyopathy (HCM). Ethan Rowin JAHA AHA Science
